TrialThe Lancet. Infectious diseases2022

Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial.

ShengLi Xia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.